CordenPharma announces an expansion of manufacturing capabilities due to the recent acquisition by International Chemical Investors Group (ICIG) of Farchemia from the Tessenderlo Group, completed on December 5th, 2012.

Farchemia, located in Bergamo, Italy, brings to CordenPharma expanded capabilities in developing and manufacturing advanced intermediates and APIs for the pharmaceutical industry in all major markets. Farchemia's portfolio is comprised of cGMP custom synthesis from lab to multi-ton scale, multi-step API process development, contract manufacturing, and full suite of proprietary generic APIs. Farchemia employs approximately 150 people and generates nearly €50 million in annual sales.